Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a featured Pulse 2.0 interview with CEO Kim Thompson covering recombinant spider silk technology, commercial-scale production and long-term strategy.
Thompson describes leveraging existing global silk infrastructure, advances in genetically engineered silkworms, expansion in Southeast Asia, and target monthly metric-ton-level production for apparel, luxury fashion, technical and defense textiles.
Kraig Biocraft Laboratories (OTCQB:KBLB) reported a new all-time production record, harvesting nearly 2.5 metric tons of recombinant spider silk cocoons in a single May 15–June 4, 2026 cycle.
This milestone advances its 2026 expansion strategy, supported by added facilities, processing underway, and repeated record-setting production cycles.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported early results from its current recombinant spider silk production cycle, with yields about 20% above internal targets, driving higher finished silk output.
If trends continue, this will be the company’s largest spider silk batch to date, with another, larger expansion cycle planned for June/July 2026. Kraig Labs’ biomaterials leadership was recently featured on the March 2026 National Geographic cover.
Kraig Biocraft Laboratories (OTCQB: KBLB) detailed its new immortalized silk gland cell platform, designed to use silkworm posterior silk gland cells for continuous recombinant protein production via natural exocytosis.
The approach aims to simplify purification, enable extended production cycles, and support scalable biomaterial manufacturing. Kraig Labs’ spider silk leadership was recently featured on the March 2026 cover of National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the creation of an immortalized silkworm silk gland cell line, which shows strong proliferation, stable passaging, and robust long-term viability in vitro. Early tests indicate high recombinant protein expression and adaptability to suspension culture, potentially enabling scalable bioprocessing for therapeutics, vaccines, and advanced biomaterials.
Kraig Biocraft Laboratories (OTCQB: KBLB) commissioned a new recombinant spider silk production rearing center, now operating as part of its April/May 2026 production cycle. The facility was deployed in under 30 days within an aggressive scale-up program.
Kraig Biocraft uses standardized facility designs and a multi-center strategy to expand capacity, improve efficiency, and add operational resiliency as it advances toward commercial-scale spider silk production. The company plans continued 2026 capacity additions and was featured on the March 2026 cover of National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) launched its April/May production cycle after a record run that produced nearly 1.8 metric tons of recombinant spider silk cocoons. The company says the new cycle aims for a substantial increase as it scales toward a long-term goal of >10 metric tons in a single month and is evaluating additional facility expansions in Southeast Asia to support capacity and downstream processing.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported progress converting its record 1.8 metric tons of recombinant spider silk cocoons into reeled silk, with conversion approximately 50% complete as of April 28, 2026. The company says finished fiber will create substantial inventory to support product development and commercial opportunities.
The company highlighted its March 2026 National Geographic cover and provided links for investor updates and images of reeled silk produced to date.
Kraig Biocraft Laboratories (OTCQB: KBLB) began processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk, a production record after exceeding 1.3 metric tons in March.
The reeling is underway with a production partner and is expected to finish by month-end, creating the company's largest-ever inventory for luxury, performance textile, and industrial uses.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced senior management is traveling to South East Asia following a record monthly production of 1.3 metric tons of recombinant spider silk cocoons on April 13, 2026. The trip will review production quality, oversee downstream reeled-silk processing, and coordinate expansion with Prodigy Silk and the production network.
The company reiterated its near-term roadmap to scale toward a 10 metric ton monthly production target and highlighted leadership coverage in National Geographic.